


Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Received: 18 August 2023

Accepted: 15 September 2023

Published online: 15 October 2023

 Check for updates

Thomas A. Wadden¹✉, Ariana M. Chao², Sriram Machineni³, Robert Kushner⁴, Jamy Ard⁵, Gitanjali Srivastava^{6,7}, Bruno Halpern⁸, Shuyu Zhang⁹, Jiaxun Chen⁹, Mathijs C. Bunck⁹, Nadia N. Ahmad⁹ & Tammy Forrester⁹

The effects of tirzepatide, a glucose-dependent insulintropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown. This double-blind, placebo-controlled trial randomized (1:1) adults with body mass index ≥ 30 or ≥ 27 kg/m² and at least one obesity-related complication (excluding diabetes), who achieved $\geq 5.0\%$ weight reduction after a 12-week intensive lifestyle intervention, to tirzepatide maximum tolerated dose (10 or 15 mg) or placebo once weekly for 72 weeks ($n = 579$). The treatment regimen estimand assessed effects regardless of treatment adherence in the intention-to-treat population. The coprimary endpoint of additional mean per cent weight change from randomization to week 72 was met with changes of -18.4% (standard error (s.e.) 0.7) with tirzepatide and 2.5% (s.e. 1.0) with placebo (estimated treatment difference -20.8 percentage points (95% confidence interval (CI) -23.2% , -18.5% ; $P < 0.001$). The coprimary endpoint of the percentage of participants achieving additional weight reduction $\geq 5\%$ was met with 87.5% (s.e. 2.2) with tirzepatide and 16.5% (s.e. 3.0) with placebo achieving this threshold (odds ratio 34.6%; 95% CI 19.2%, 62.6%; $P < 0.001$). The most common adverse events with tirzepatide were gastrointestinal, with most being mild to moderate in severity. Tirzepatide provided substantial additional reduction in body weight in participants who had achieved $\geq 5.0\%$ weight reduction with intensive lifestyle intervention. ClinicalTrials.gov registration: [NCT04657016](https://clinicaltrials.gov/ct2/show/study/NCT04657016).

The adverse effects of obesity are well known to healthcare professionals and persons who live with this chronic disease^{1–4}, as are the benefits of weight reduction. Decreasing baseline body weight by 5–10% reduces the likelihood of developing type 2 diabetes while also improving cardiometabolic risk factors (for example, blood pressure) and other obesity-related complications (for example, osteoarthritis)^{5–8}.

Intensive lifestyle intervention is recommended as the cornerstone of obesity management^{3,5,8–10}. It consists of a reduced-calorie diet

(for example, 1,200–1,500 kcal per day based on weight or sex), physical activity (≥ 150 min per week) and frequent behavioral counseling (for example, ≥ 14 sessions over 6 months), and induces mean reductions of 5–8% of baseline weight with accompanying improvements in health⁵. Its overall effectiveness, however, is limited by two factors. Large weight reductions are critical for achieving optimal control of obesity-related complications (for example, obstructive sleep apnea and nonalcoholic steatohepatitis)^{6–8} and decreasing cardiovascular

A full list of affiliations appears at the end of the paper. ✉e-mail: wadden@penmedicine.upenn.edu




Fig. 1 | Trial profile. SURMOUNT-3 CONSORT flow diagram. MTD, maximum tolerated dose (10 or 15 mg). TZP, tirzepatide.

mortality^{11–14}, but <20% of patients treated with lifestyle interventions lose $\geq 15\%$ of baseline weight¹⁵. Patients also regain one-third of lost weight in the year following treatment, with increasing weight regain over time^{5,16}. Weight regain after diet and exercise intervention is attributable, in part, to persistent metabolic adaptations in which patients' hunger hormones increase, satiety hormones decrease and energy expenditure declines out of proportion to the amount of weight lost^{17–19} such that an even lower energy intake is needed to maintain the weight-reduced state.

New incretin-based, antiobesity medications could bolster the results of intensive lifestyle intervention²⁰. Semaglutide 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist, originally approved at a lower dose for control of type 2 diabetes and which, in persons with obesity or overweight (but not diabetes), reduces baseline body weight by 15% at up to 2 years (versus 2–3% for placebo)^{21,22}. It decreases energy intake principally by modification of hunger and satiety signaling in select neural regions²¹. Tirzepatide is a single molecule that combines glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonism²³ to exert synergistic effects on appetite (for example, hunger and satiety), energy intake and metabolic function^{24–26}. It is approved in many geographies including the USA, European Union and Japan as a once-weekly subcutaneous injectable for type 2 diabetes and is currently under review for chronic weight management^{26–28}. In the SURMOUNT-1 trial, patients with obesity or overweight (but not diabetes) who received tirzepatide 15 mg, with monthly brief lifestyle counseling, lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with accompanying reductions in cardiometabolic risk factors²⁷.

Expert panels have suggested the use of antiobesity medications following intensive lifestyle intervention to induce additional weight reduction (which may be needed to achieve optimal control of obesity-related complications) or, at a minimum, to prevent weight regain^{5,7,9,10}. The present trial evaluated the efficacy of tirzepatide at 72 weeks postrandomization in adults with obesity or overweight (but not diabetes) who successfully lost $\geq 5\%$ of baseline weight during a 12-week lead-in period that provided intensive lifestyle intervention.

Results

Patient disposition

Intensive lifestyle intervention lead-in period. A total of 972 participants were assessed for eligibility at screening, of whom 806 were enrolled into the 12-week intensive lifestyle intervention lead-in period (Fig. 1). The first participant was enrolled on 12 April 2021 and the last on 3 September 2021. The key demographics and clinical characteristics of these participants have previously been published²⁸.

Of the 806 participants enrolled, 579 (71.8%) who achieved $\geq 5\%$ weight reduction at the end of the lead-in period and were otherwise eligible to proceed to the next phase of the study were randomized to either tirzepatide maximum tolerated dose (MTD, $n = 287$) or placebo ($n = 292$) (Fig. 1). Mean body weight and body mass index (BMI) in these 579 participants decreased from 109.5 kg and 38.6 kg/m², respectively, at screening to 101.9 kg and 35.9 kg/m², respectively, at randomization, representing an average 6.9% reduction in body weight after the 12-week intensive lifestyle intervention (Table 1). Weight reduction during lead-in was accompanied by reductions in waist circumference,

Table 1 | Clinical characteristics and changes during intensive lifestyle intervention lead-in period

	Mean (s.d.)								
	Tirzepatide MTD (n=287)			Placebo (n=292)			Total (n=579)		
	Start of intensive lifestyle intervention lead-in	Start of double-blind treatment period (randomization)	Change during lead-in	Start of intensive lifestyle intervention lead-in	Start of double-blind treatment period (randomization)	Change during lead-in	Start of intensive lifestyle intervention lead-in	Start of double-blind treatment period (randomization)	Change during lead-in
Body weight, kg	110.1 (23.9)	102.5 (22.1)	−7.6 (2.9) kg −6.9 (1.9)%	108.9 (22.2)	101.3 (20.7)	−7.6 (2.8) kg −7.0 (2.0)%	109.5 (23.0)	101.9 (21.4)	−7.6 (2.9) kg −6.9 (2.0)%
BMI, kg/m ²	38.7 (6.6)	36.1 (6.1)	−2.7 (0.9)	38.4 (6.8)	35.7 (6.4)	−2.7 (0.9)	38.6 (6.7)	35.9 (6.3)	−2.7 (0.9)
Waist circumference, cm	115.9 (15.6)	109.3 (15.2)	−6.6 (5.4)	116.3 (15.3)	109.6 (15.1)	−6.7 (4.9)	116.1 (15.4)	109.4 (15.0)	−6.7 (5.2)
Blood pressure, mmHg									
Systolic	125.9 (12.7)	121.4 (12.7)	−4.5 (11.4)	126.0 (13.3)	120.5 (12.4)	−5.4 (11.3)	126.0 (13.0)	121.0 (12.6)	−5.0 (11.4)
Diastolic	81.8 (8.5)	79.1 (8.9)	−2.6 (8.1)	81.2 (8.4)	78.1 (9.2)	−3.1 (8.2)	81.5 (8.5)	78.6 (9.1)	−2.9 (8.1)
Pulse rate, beats per min	73.4 (10.0)	72.0 (10.8)	−1.4 (10.2)	72.2 (9.9)	70.4 (10.3)	−1.8 (9.1)	72.8 (9.9)	71.2 (10.6)	−1.6 (9.6)
HbA _{1c} , %	5.5 (0.4)	5.3 (0.4)	−0.1 (0.3)	5.5 (0.4)	5.4 (0.4)	−0.1 (0.3)	5.5 (0.4)	5.4 (0.4)	−0.1 (0.3)
Fasting glucose, mg/dl ¹	95.7 (9.9)	92.6 (11.3)	−3.1 (10.1)	94.0 (8.8)	91.3 (9.4)	−2.8 (10.0)	94.9 (9.4)	91.9 (10.4)	−2.9 (10.0)
Fasting insulin, mIU/l ¹	97.7 (75.3)	70.7 (59.0)	−18.5 (52.9)%	93.6 (87.7)	62.9 (44.4)	−22.3 (41.3)%	95.6 (81.7)	66.7 (52.2)	−20.4 (47.4)%
Lipid level, mg/dl ¹									
Total cholesterol	191.4 (36.8)	185.2 (37.2)	−2.5 (13.7)%	196.2 (39.0)	185.3 (38.2)	−4.9 (12.1)%	193.8 (38.0)	185.3 (37.6)	−3.7 (13.0)%
Non-HDL cholesterol	141.9 (35.8)	136.7 (35.6)	−2.3 (18.1)%	145.6 (37.5)	135.90 (35.7)	−5.5 (15.4)%	143.7 (36.7)	136.3 (35.6)	−3.9 (16.8)%
HDL cholesterol	49.6 (14.0)	48.4 (12.7)	−0.8 (13.9)%	50.6 (13.8)	49.3 (12.9)	−1.5 (13.4)%	50.1 (13.9)	48.9 (12.8)	−1.2 (13.7)%
LDL cholesterol	113.7 (30.4)	112.5 (32.5)	0.8 (24.3)%	118.0 (32.4)	112.3 (32.3)	−3.6 (18.2)%	115.9 (31.5)	112.4 (32.4)	−1.4 (21.5)%
VLDL cholesterol	60.3 (27.2)	54.4 (21.7)	−3.8 (33.1)%	62.1 (30.9)	54.2 (24.4)	−5.5 (34.3)%	61.2 (29.1)	54.3 (23.1)	−4.7 (33.7)%
Triglycerides	141.2 (112.3)	121.4 (55.7)	−4.4 (33.4)%	138.2 (73.5)	118.6 (53.3)	−6.0 (34.1)%	139.7 (94.7)	120.0 (54.5)	−5.2 (33.8)%
Free fatty acids, mEq/l ¹	0.6 (0.2)	0.6 (0.3)	23.0 (82.0)%	0.5 (0.2)	0.6 (0.2)	29.9 (86.3)%	0.5 (0.2)	0.6 (0.2)	26.5 (84.2)%
eGFR, ml/min ^{1.73} m ^{−2}	99.0 (17.1)	95.6 (17.1)	−3.4 (10.4)	100.3 (15.7)	97.1 (16.7)	−3.3 (8.9)	99.6 (16.4)	96.4 (16.9)	−3.3 (9.7)
Patient-reported outcomes									
SF-36v2 physical functioning domain score ^a	48.9 (7.8)	51.7 (6.7)	2.7 (7.7)	48.6 (7.8)	51.7 (6.8)	3.1 (5.8)	48.8 (7.8)	51.7 (6.7)	2.9 (6.8)
IWQOL-Lite-CT physical function composite score ^b	59.5 (22.7)	73.4 (21.3)	13.9 (17.6)	57.4 (24.3)	71.4 (22.0)	13.9 (17.7)	58.4 (23.5)	72.4 (21.6)	13.9 (17.7)

eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IWQOL-Lite-CT, Impact of Weight on Quality of Life-Lite-Clinical Trials Version; LDL-C, low-density lipoprotein cholesterol; SF-36v2, Short Form-36v2 Health Survey acute form; VLDL-C, very-low-density lipoprotein cholesterol. ^aSF-36v2 measures health-related quality of life and general health status. SF-36v2 scores are norm based—that is, scores are transformed to a scale in which the 2009 US general population has a mean score of 50 and s.d. of 10. An increase in score represents an improvement in health status. ^bIWQOL-Lite-CT measures weight-specific, health-related quality of life. All items are rated on either a five-point frequency scale ('never' to 'always') or a five-point truth scale ('not at all true' to 'completely true'). Scores are transformed to a scale of 0–100, with higher scores reflecting better levels of functioning.

systolic and diastolic blood pressure, glycated hemoglobin A_{1c} (HbA_{1c}), fasting glucose and fasting insulin. There were mean improvements in all lipid levels, except for high-density lipoprotein (HDL) cholesterol and free fatty acids (Table 1).

Tirzepatide versus placebo postrandomization. The majority of the 579 randomized participants were white (86.0%) and female (62.9%), with an overall mean age of 45.6 years (Table 2). The average duration of obesity was 15.1 years, and 66.1% had a medical history of one or more obesity-related complications. Demographics and clinical characteristics at randomization (week 0), as well as weight reduction and cardiometabolic changes during the lead-in period, were similar across the tirzepatide MTD (10 or 15 mg) and placebo groups (Tables 1 and 2 and Extended Data Table 1).

Of the 579 randomized participants, 479 (82.7%) completed the study (87.8% on tirzepatide MTD and 77.7% on placebo) and 429 (74.1%) completed the study on treatment (78.7% on tirzepatide MTD and 69.5%

on placebo). The most common reasons for discontinuation of study treatment were adverse event (10.5%, detailed in Table 3) and withdrawal by subject (6.3%) in the tirzepatide MTD group, and withdrawal by subject (14.4%) and lost to follow-up (6.5%) in the placebo group.

In tirzepatide-treated participants, 248 (86.4%) had a tirzepatide MTD of 15 mg. In this study, all randomized participants took at least one dose of the study intervention (tirzepatide MTD or placebo). Therefore, the intention-to-treat population is the same as the modified intention-to-treat population.

Primary outcomes

Figure 2a,b shows the mean percentage reduction in body weight from randomization to week 72. For the treatment regimen estimand (TRE) the mean change at week 72 was −18.4% (s.e. 0.7) with tirzepatide MTD and 2.5% (s.e. 1.0) with placebo. Tirzepatide MTD was superior to placebo, with an estimated treatment difference relative to placebo of −20.8 percentage points (95% CI −23.2, −18.5; *P* < 0.001) (Table 4).

Table 2 | Baseline characteristics (at randomization) in all randomized participants

Characteristics	Tirzepatide MTD (n=287)	Placebo (n=292)	Total (n=579)
Age, mean (s.d.), years	45.4 (12.6)	45.7 (11.8)	45.6 (12.2)
Sex, no. (%)			
Female	181 (63.1)	183 (62.7)	364 (62.9)
Male	106 (36.9)	109 (37.3)	215 (37.1)
Race, no. (%) ^a			
Asian	2 (0.7)	2 (0.7)	4 (0.7)
Black or African American	31 (10.8)	32 (11.0)	63 (10.9)
Multiple	6 (2.1)	2 (0.7)	8 (1.4)
American Indian or Alaskan	2 (0.7)	4 (1.4)	6 (1.0)
White	246 (85.7)	252 (86.3)	498 (86.0)
Ethnicity, no. (%) ^a			
Hispanic or Latino	151 (52.6)	161 (55.1)	312 (53.9)
Not Hispanic or Latino	132 (46.0)	129 (44.2)	261 (45.1)
Not reported	4 (1.4)	2 (0.7)	6 (1.0)
Country			
Argentina	43 (15.0)	44 (15.1)	87 (15.0)
Brazil	59 (20.6)	60 (20.5)	119 (20.6)
USA	185 (64.5)	188 (64.4)	373 (64.4)
Duration of obesity, mean (s.d.), years ^b	15.4 (11.6)	14.8 (10.8)	15.1 (11.2)
BMI category, no. (%)			
<27	5 (1.7)	12 (4.1)	17 (2.9)
≥27 to <30	32 (11.1)	38 (13.0)	70 (12.1)
≥30 to <35	100 (34.8)	107 (36.6)	207 (35.8)
≥35 to <40	95 (33.1)	79 (27.1)	174 (30.1)
≥40	55 (19.2)	56 (19.2)	111 (19.2)
Obesity-related complications, n (%) ^c			
Hypertension	95 (33.1)	104 (35.6)	199 (34.4)
Dyslipidemia	71 (24.7)	81 (27.7)	152 (26.3)
ASCVD	5 (1.7)	6 (2.1)	11 (1.9)
Polycystic ovarian syndrome	8 (4.4)	8 (4.4)	16 (4.4)
Obstructive sleep apnea	25 (8.7)	34 (11.6)	59 (10.2)
Osteoarthritis	43 (15.0)	48 (16.4)	91 (15.7)
Anxiety/depression	61 (21.3)	55 (18.8)	116 (20.0)
NAFLD	9 (3.1)	16 (5.5)	25 (4.3)
Asthma or COPD	21 (7.3)	31 (10.6)	52 (9.0)
Gout	6 (2.1)	9 (3.1)	15 (2.6)
Number of weight-related complications, n (%) ^c			
0	96 (33.4)	100 (34.2)	196 (33.9)
1	102 (35.5)	81 (27.7)	183 (31.6)
2	48 (16.7)	54 (18.5)	102 (17.6)
3	22 (7.7)	36 (12.3)	58 (10.0)
4	14 (4.9)	14 (4.8)	28 (4.8)
≥5	5 (1.7)	7 (2.4)	12 (2.1)

ASCVD, atherosclerotic cardiovascular disease; COPD, chronic obstructive pulmonary disease; NAFLD, non-alcoholic fatty liver disease. ^aRace and ethnicity were determined by the participant according to fixed selection categories. ^bDuration of obesity was assessed by self-report. ^cBaseline medical conditions were assessed through a review of participants' medical history.

The mean change in body weight for the efficacy estimand was −21.1% (s.e. 0.6) with tirzepatide MTD and 3.3% (s.e. 0.6) with placebo. The estimated treatment difference was −24.5 percentage points (95% CI −26.1, −22.8; $P < 0.001$) for tirzepatide MTD versus placebo. Absolute body weight over time is shown in Extended Data Fig. 1.

For the TRE, 87.5% (251) of participants in the tirzepatide MTD group lost an additional ≥5% of body weight from randomization to week 72 compared with 16.5% (48) in the placebo group (odds ratio (OR) 34.6 (95% CI 19.2, 62.6); $P < 0.001$) (Fig. 2c and Table 4). For the efficacy estimand, 94.4% (268) of participants in the tirzepatide MTD group had an additional body weight reduction of ≥5% from randomization compared with 10.7% (31) in the placebo group (OR 130.4 (95% CI 70.0, 242.8); $P < 0.001$) (Fig. 2d).

Secondary outcomes

Change in body weight. At week 72, more participants on tirzepatide MTD than placebo achieved reductions in body weight of ≥10, ≥15 and ≥20% from randomization ($P < 0.001$; Fig. 2c,d and Table 4).

At 72 weeks, for the TRE, 94.0% (270) of participants in the tirzepatide MTD group maintained ≥80% of body weight lost during the 12-week lead-in period compared with 43.8% (128) in the placebo group (OR 19.7; 95% CI 10.3, 37.6; $P < 0.001$; Fig. 2e and Table 4). For the efficacy estimand, 98.6% (280) of participants in the tirzepatide MTD group met this endpoint compared with 37.8% (110) in the placebo group (OR 101.6; 95% CI 39.2, 263.6; $P < 0.001$; Fig. 2e).

Overall, for the TRE, intensive lifestyle intervention followed by 72 weeks of tirzepatide led to a total weight change of −24.3% compared with −4.5% with intensive lifestyle intervention followed by placebo (estimated treatment difference −19.9 percentage points (95% CI −23.5, −16.2) (Fig. 2f). For the efficacy estimand, intensive lifestyle intervention followed by 72 weeks of tirzepatide led to a total weight change of −26.6% compared with −3.8% with intensive lifestyle intervention followed by placebo (estimated treatment difference −22.8 percentage points (95% CI −24.3, −21.2; Fig. 2f and Extended Data Table 2).

Accordingly, there was a reduction in BMI with tirzepatide compared with placebo from randomization to week 72 (efficacy estimand: tirzepatide, −7.7 kg/m² versus placebo, 1.2 kg/m²; estimated treatment difference −8.9 kg/m² (95% CI −9.6, −8.3; Table 4). Total change in BMI with intensive lifestyle intervention followed by 72 weeks of tirzepatide MTD was −10.4 kg/m² compared with −1.4 kg/m² with intensive lifestyle intervention followed by placebo (efficacy estimand: estimated treatment difference −8.9 kg/m² (95% CI −9.6, −8.3; Extended Data Table 2).

Cardiometabolic risk factors and physical function. At week 72 the change from randomization in waist circumference with tirzepatide MTD was superior to placebo using the TRE (tirzepatide, −14.6 cm versus placebo, 0.2 cm; estimated treatment difference, −14.8 cm (95% CI −17.2, −12.5; $P < 0.001$; Table 4). Results were consistent for the efficacy estimand (tirzepatide, −16.8 cm versus placebo, 1.1 cm; estimated treatment difference −17.9 cm (95% CI −19.5, −16.3; $P < 0.001$). Improvements with tirzepatide MTD, from randomization to week 72, were greater versus placebo in both systolic blood pressure (tirzepatide, −5.1 mmHg versus placebo, 4.1 mmHg; estimated treatment difference −9.2 mmHg (−11.2, −7.2) and diastolic blood pressure (tirzepatide, −3.2 mmHg versus placebo, 2.3 mmHg; estimated treatment difference −5.5 mmHg (−6.9, −4.1) using the efficacy estimand (Table 4 and Extended Data Fig. 2). Treatment with tirzepatide MTD resulted in further improvements across all fasting lipid levels (HDL, LDL, VLDL, total cholesterol, triglycerides and free fatty acids), glycemic control (fasting glucose and HbA1c) and fasting insulin compared with placebo at 72 weeks from randomization (Table 4). In addition, 4.9 and 2.8% of participants in the tirzepatide group compared with 1.0 and 1.7% of participants in the placebo group were reported as having a decrease in intensity of antihypertensive and lipid-lowering medications, respectively. Conversely, 2.4 and 0.3% of participants in the tirzepatide group

Table 3 | Adverse events during the double-blind period and safety follow-up period (safety analysis set)

	No. (%)	
	Tirzepatide MTD (n=287)	Placebo (n=292)
Participants with ≥1 adverse event	250 (87.1)	224 (76.7)
Serious adverse events	17 (5.9)	14 (4.8)
Death ^a	1 (0.3)	1 (0.3)
Adverse events leading to treatment discontinuation ^b	30 (10.5)	6 (2.1)
Nausea	24 (8.4)	4 (1.4)
Vomiting	6 (2.1)	0
Diarrhea	3 (1.0)	0
Dyspepsia	3 (1.0)	0
Constipation	2 (0.7)	0
Adverse events occurring in ≥5% of participants in any treatment group		
Nausea	114 (39.7)	41 (14.0)
Diarrhea	89 (31.0)	27 (9.2)
Constipation	66 (23.0)	20 (6.8)
COVID-19	66 (23.0)	74 (25.3)
Vomiting	52 (18.1)	4 (1.4)
Injection site reaction	32 (11.1)	3 (1.0)
Abdominal pain	30 (10.5)	7 (2.4)
Decreased appetite	27 (9.4)	12 (4.1)
Dyspepsia	27 (9.4)	9 (3.1)
Headache	27 (9.4)	22 (7.5)
Upper respiratory tract infection	25 (8.7)	21 (7.2)
Alopecia	20 (7.0)	4 (1.4)
Dizziness	20 (7.0)	6 (2.1)
Fatigue	20 (7.0)	9 (3.1)
Flatulence	19 (6.6)	8 (2.7)
Gastroesophageal reflux disease	19 (6.6)	7 (2.4)
Back pain	17 (5.9)	15 (5.1)
Eructation	16 (5.6)	3 (1.0)
Influenza	12 (4.2)	25 (8.6)
Urinary tract infection	11 (3.8)	15 (5.1)
Anxiety	9 (3.1)	19 (6.5)
Arthralgia	7 (2.4)	15 (5.1)
Sinusitis	6 (2.1)	16 (5.5)
Adverse events of special interest		
Severe or serious gastrointestinal events	16 (5.6)	5 (1.7)
Malignancies	5 (1.7)	3 (1.0)
Severe or serious acute gall bladder diseases	2 (0.7)	0
MACE (adjudication confirmed)	1 (0.3)	1 (0.3)
Pancreatitis (adjudication confirmed)	1 (0.3)	1 (0.3)
Severe or serious renal events	1 (0.3)	0
Severe or serious MDD/suicidal behavior and ideation	1 (0.3)	0
Severe or serious arrhythmias and cardiac conduction disorders	0	1 (0.3)
Severe hypoglycemia	0	0

Table 3 (continued) | Adverse events during the double-blind period and safety follow-up period (safety analysis set)

	No. (%)	
	Tirzepatide MTD (n=287)	Placebo (n=292)
Other adverse events of interest		
Cholelithiasis	4 (1.4)	3 (1.0)
Acute cholecystitis	1 (0.3)	0
Chronic cholecystitis	0	1 (0.3)

Events are listed according to Medical Dictionary for Regulatory Activities, v.26.0, preferred terms. MACE, major adverse cardiovascular event; MDD, major depressive disorder. ^aDeaths are also included as serious adverse events and discontinuations due to adverse event. ^bOnly adverse events occurring in ≥2 participants in any treatment group are presented.

were reported to have experienced an increase in intensity of anti-hypertensive and lipid-lowering therapies, respectively, compared with 6.5 and 2.1% of participants in the placebo group.

Participant-reported physical function improved more with tirzepatide than with placebo from randomization to week 72 (Table 4). This was observed with both the physical functioning domain score for Short Form-36v.2 Health Survey (SF-36v2) (tirzepatide, 3.3 versus placebo, −0.6; estimated treatment difference 3.9 (95% CI 2.8, 4.9)) and the Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) physical function composite score (tirzepatide, 13.9 versus placebo, 1.1; estimated treatment difference 12.8 (95% CI 9.7, 16.0)) using the efficacy estimand.

Changes in cardiometabolic parameters and patient-reported outcomes from the start of the lead-in period (week −12) to week 72 are reported in Extended Data Table 2.

Safety

Overall, 87.1% of the 287 tirzepatide-treated participants reported at least one treatment-emergent adverse event compared with 76.7% of the 292 placebo-treated participants (Table 3). The most frequently reported adverse events were gastrointestinal (nausea, diarrhea and constipation). These occurred in more participants in the tirzepatide MTD group than placebo, were mostly mild to moderate in severity and occurred primarily during dose escalation (Extended Data Fig. 3). Antiemetic medication use was reported by 78 participants (27.2%) treated with tirzepatide and by 20 (6.8%) treated with placebo. Antidiarrheal medication use was reported by 23 participants (8.0%) treated with tirzepatide and by six (2.1%) treated with placebo.

Serious adverse events were reported by 31 participants (5.4%) overall. Occurrence was similar in participants treated with tirzepatide (5.9%) and placebo (4.8%) (Table 3). Two deaths (both myocardial infarction) were reported during the study, one in the tirzepatide MTD group and one in the placebo group. Both events were considered not to be related to the study treatment by the investigator.

Adjudication-confirmed cases of pancreatitis were reported in 0.3% (one) of participants in the tirzepatide MTD group and 0.3% (one) of participants in the placebo group from randomization to safety follow-up (Table 3). Cholelithiasis was reported in 1.4% (four) of participants in the tirzepatide group and 1.0% (three) of participants in the placebo group. There was one case (0.3%) of acute cholecystitis in the tirzepatide group and none in the placebo group. Malignancies were reported in 1.7% (five) of participants in the tirzepatide MTD group and 1.0% (three) of participants in the placebo group. None of the malignancies were considered related to the study treatment by the investigators, and no cases of medullary thyroid cancer or pancreatic cancer were reported. Additional safety measures are reported in Extended Data Table 3.




Fig. 2 | Effect of once-weekly tirzepatide on body weight in comparison with placebo. **a**, Least-square mean (LSM) (s.e.) per cent change in body weight from randomization to week 72 derived from an analysis of covariance model for the TRE (tirzepatide MTD, $n = 287$ participants; placebo, $n = 292$ participants), and from MMRM analysis for the efficacy estimand (tirzepatide MTD, $n = 284$ participants; placebo, $n = 291$ participants). **b**, LSM (s.e.) per cent change in body weight over time from randomization to 72 weeks, derived from MMRM analysis for the efficacy estimand; week 72 estimates for the TRE are also shown. **c,d**, LSM (s.e.) percentages of participants who had body weight reduction of at least 5, 10, 15, 20 or 25% from randomization to week 72. **c**, Percentage of participants reaching weight reduction thresholds (TRE) was calculated using logistic

regression with missing values imputed by hybrid imputation (tirzepatide MTD, $n = 287$ participants; placebo, $n = 292$ participants). **d**, Percentage of participants reaching weight reduction thresholds (efficacy estimand) was obtained by logistic regression with missing values at week 72 imputed from MMRM analysis (tirzepatide MTD, $n = 284$ participants; placebo, $n = 291$ participants). **e**, LSM proportion of participants that maintained $\geq 80\%$ of body weight reductions achieved at the end of the lead-in period. Both TRE and efficacy estimand shown. **f**, Mean (95% CI) per cent change in body weight over time from the start of the intensive lifestyle intervention lead-in period (-12 weeks) to 72 weeks, derived from observed values, irrespective of treatment adherence; week 72 estimates for TRE and efficacy estimand (EFF), are also shown.

Table 4 | Efficacy findings from randomization (week 0) to week 72

	LSM (s.e.)		Treatment comparison	
	Tirzepatide MTD (n=287)	Placebo (n=292)	Difference from placebo (95% CI)	P value
Primary endpoints				
Per cent change in body weight	−18.4 (0.7)	2.5 (1.0)	ETD −20.8 (−23.2, −18.5)	<0.001
Participants achieving ≥5% body weight reduction, %	87.5 (2.2)	16.5 (3.0)	OR 34.6 (19.2, 62.6)	<0.001
Key secondary endpoints				
Participants achieving body weight reduction, %				
≥10%	76.7 (2.7)	8.9 (2.4)	OR 34.7 (17.6, 68.3)	<0.001
≥15%	65.4 (3.0)	4.2 (1.8)	OR 48.2 (19.2, 121.0)	<0.001
≥20%	44.7 (3.0)	2.2 (1.3)	OR 40.4 (12.2, 133.8)	<0.001
Participants maintaining ≥80% of lead-in body weight lost at week 72, %	94.0 (1.7)	43.8 (3.9)	ETD 19.7 (10.3, 37.6)	<0.001
Change in waist circumference, cm	−14.6 (0.7)	0.2 (1.0)	ETD −14.8 (−17.2, −12.5)	<0.001
Additional secondary endpoints				
Change in body weight, kg	−21.5 (0.7)	3.5 (0.7)	ETD −25.0 (−26.9, −23.2)	NR ^a
Change in BMI, kg/m ²	−7.7 (0.2)	1.2 (0.2)	ETD −8.9 (−9.6, −8.3)	NR
Change in SBP, mmHg	−5.1 (0.7)	4.1 (0.7)	ETD −9.2 (−11.2, −7.2)	NR
Change in DBP, mmHg	−3.2 (0.5)	2.3 (0.5)	ETD −5.5 (−6.9, −4.1)	NR
Fasting lipids				
Per cent change in total cholesterol	−3.0 (1.0)	5.2 (1.1)	ETD −7.8 (−10.4, −5.1)	NR
Per cent change in non-HDL cholesterol	−9.8 (1.3)	5.6 (1.5)	ETD −14.6 (−17.9, −11.2)	NR
Per cent change in HDL cholesterol	15.4 (1.2)	3.6 (1.1)	ETD 11.4 (8.2, 14.7)	NR
Per cent change in LDL cholesterol	−6.1 (1.4)	6.1 (1.7)	ETD −11.5 (−15.3, −7.5)	NR
Per cent change in VLDL cholesterol	−25.6 (1.6)	3.0 (2.3)	ETD −27.8 (−32.1, −23.2)	NR
Per cent change in triglycerides	−25.8 (1.6)	3.0 (2.3)	ETD −28.0 (−32.3, −23.4)	NR
Per cent change in free fatty acids	−33.1 (2.2)	−15.0 (3.0)	ETD −21.3 (−28.4, −13.6)	NR
Change in fasting glucose, mg dl ^{−1}	−8.8 (0.8)	2.4 (0.9)	ETD −11.2 (−13.5, −8.8)	NR
Change in HbA1c, %	−0.5 (0.0)	0.0 (0.0)	ETD −0.5 (−0.5, −0.4)	NR
Per cent change in fasting insulin	−39.1 (2.5)	17.3 (5.0)	ETD −48.1 (−53.7, −41.7)	NR
Patient-reported outcomes				
Change in SF-36v2 Physical Functioning domain score ^b	3.3 (0.4)	−0.6 (0.4)	ETD 3.9 (2.8, 4.9)	NR
Change in IWQOL-Lite-CT Physical Function composite score ^c	13.9 (1.1)	1.1 (1.2)	ETD 12.8 (9.7, 16.0)	NR
Prespecified exploratory endpoints				
Participants achieving body weight reduction ≥25%, %	28.7 (2.7)	1.2 (0.9)	OR 33.70 (8.84, 128.52)	NR

Primary, key secondary and prespecified exploratory endpoints are presented using the TRE, and additional secondary endpoints are presented using the efficacy estimand. Primary and key secondary endpoints were controlled for type1 error at a two-sided significance level of 0.05 within each estimand via a graphical testing approach. Other endpoints were not controlled for type1 error. DBP, diastolic blood pressure; ETD, estimated treatment difference; NR, not reported; SBP, systolic blood pressure. ^aP-values are not reported for additional secondary and prespecified exploratory endpoints because these were not controlled for type1 error. ^bSF-36v2 measures health-related quality of life and general health status. SF-36v2 scores are norm based—that is, transformed to a scale in which the 2009 US general population has a mean score of 50 and s.d. of 10. An increase in score represents an improvement in health status. ^cIWQOL-Lite-CT measures weight-specific, health-related quality of life. All items are rated on either a five-point frequency scale ('never' to 'always') or a five-point truth scale ('not at all true' to 'completely true'). Scores are transformed to a scale of 0–100, with higher scores reflecting better levels of functioning.

Exploratory outcomes

For the prespecified exploratory endpoint of achieving ≥25% body weight reduction from randomization, for the TRE, 28.7% (82) of tirzepatide-treated participants compared with 1.2% (four) in the placebo group met this target (OR 33.7 (95% CI 8.8, 128.5); Table 4). Results were consistent for the efficacy estimand (tirzepatide, 36.3% versus placebo, 0.3%; OR 124.6 (95% CI 24.9, 623.2); Fig. 2d).

Discussion

Tirzepatide substantially increased the magnitude of weight loss when administered following an initial 12-week intensive lifestyle intervention that reduced baseline body weight by an average of 6.9% in successful

program completers. As measured from randomization (week 0) to week 72, participants who received tirzepatide MTD of 10 or 15 mg lost an additional 18.4% of body weight, compared with a gain of 2.5% for placebo. In total, 87.5% of tirzepatide-treated participants lost an additional 5% or more of their randomization weight compared with 16.5% of placebo-treated participants, with tirzepatide also demonstrating superiority in the achievement of all other categorical weight losses. These findings indicate that individuals with overweight or obesity who have lost approximately 5–10% of their body weight with supervised lifestyle intervention—or potentially through their own self-directed diet and exercise efforts—could expect to achieve further clinically meaningful weight loss with the addition of tirzepatide.

The strength of tirzepatide is underscored by comparison with a similarly designed trial of liraglutide (3.0 mg), approved for chronic weight management. After losing an average 6.0% of baseline weight in a comparable lead-in program, participants who received liraglutide achieved an additional 6.2% reduction in randomization weight at 56 weeks compared with a 0.2% reduction for placebo²⁹. The liraglutide trial provided a total of 17 lifestyle counseling sessions during the medication phase of the study compared with only quarterly visits in the present trial. This decreased frequency of counseling visits could explain the greater weight regain in the placebo group in the present study. The only other similarly designed trial of a medication approved for chronic weight management found that orlistat (120 mg three times daily) was not effective in inducing additional weight loss over 1 year when administered following an average 11.0% reduction achieved with intensive lifestyle intervention³⁰. Patients treated by both orlistat and placebo regained one-third or more of their lost weight. Tirzepatide was also superior to placebo on a traditional measure of weight loss maintenance—the proportion of participants who maintained a predefined percentage of their initial weight loss. In the present study, 94% of tirzepatide-treated participants, compared with 44% of those who received placebo, maintained $\geq 80\%$ of their weight loss achieved in the lead-in period. These results compare favorably with those achieved with both liraglutide and orlistat but perhaps, more importantly, with the results of traditional lifestyle intervention. Individuals who receive such intervention typically regain one-third of their lost weight in the year following treatment completion³¹. Regain can be decreased to 10–15% at 1 year with participation in a weight loss maintenance program, offered in person or by phone, which provides continued lifestyle counseling on a monthly or more frequent basis³². However, after 2.5 years of such monthly phone-based counseling only 45% of participants maintained ≥ 4 kg of an original mean 8.5 kg loss achieved during a 6 month lead-in period³³. These findings reveal the potential benefits of tirzepatide, relative to traditional weight loss maintenance counseling, in not only sustaining weight reduction achieved with intensive lifestyle intervention but in adding to it. Long-term comparative studies for weight loss maintenance are needed.

The cumulative 24.3% reduction in body weight achieved with intensive lifestyle intervention, followed by tirzepatide, approximates the 1 year weight loss induced with sleeve gastrectomy³⁴. The overall BMI reduction of 10 kg/m² represents a downward shift of about two BMI categories. Participants treated with lifestyle interventions have long sought to achieve a similar magnitude of weight loss, principally to improve their health and quality of life^{35,36}. Tirzepatide enhanced the improvements in cardiometabolic risk factors that were achieved in the lead-in period. Systolic and diastolic BP improved by an additional -5.1 and -3.2 mmHg, respectively, lipids parameters improved by an additional -3% to -26% and fasting insulin further declined by 39%. Self-reported physical function improved by 3.3 points on the SF-36v2 physical functioning domain score and by 13.9 points on the IWQOL-Lite-CT physical function composite. These improvements underscore the additional benefits that patients may receive from treatment with tirzepatide after first losing weight with intensive lifestyle intervention, or potentially with their own self-directed diet and activity programs. By contrast, many of the cardiometabolic improvements achieved during the lead-in reverted toward baseline in the placebo group.

The safety profile of tirzepatide in this trial was consistent with findings from previous trials of tirzepatide when evaluated for the treatment of obesity^{27,37} or type 2 diabetes³⁸, as well as with the safety profile of the GLP-1 receptor agonist class in patients with obesity or overweight^{39,40}. Mild-to-moderate gastrointestinal events were the most frequent treatment-emergent adverse events, mostly transient and occurring during dose escalation. Compared with the tirzepatide 15 mg group in SURMOUNT-1, the tirzepatide group in this study had modestly higher rates of gastrointestinal adverse events and treatment

discontinuation due to adverse events. Other trials that combined intensive lifestyle intervention with pharmacotherapy have also shown higher rates of gastrointestinal events compared with trials investigating pharmacotherapy without intensive lifestyle intervention (for example, STEP-3 compared with STEP-1 for semaglutide 2.4 mg and SCALE-MAINTENANCE compared with SCALE for liraglutide 3.0 mg)^{21,29,41,42}. It has been speculated that caloric restriction could lead to a reduction in GLP-1 and other gastrointestinal satiety hormones⁴³. Whether this worsens initial gastrointestinal tolerability to incretin-based therapy and is a possible explanation for the observed findings requires further investigation.

Much remains to be learned about how lifestyle intervention and the new incretin-based antiobesity medications can be optimally used together. If the goal of combining these therapies is to increase total weight loss, results of the present trial and SCALE-MAINTENANCE²⁹ suggest that introducing the intensive lifestyle intervention first (for approximately 12 weeks) followed by the addition of medication, as in the present study, could maximize weight reduction. The weight reduction observed with tirzepatide MTD in the 72 week, double-blind period of the current trial was similar to that achieved with tirzepatide 10 and 15 mg over 72 weeks in the SURMOUNT-1 study. Therefore, the sequential use of these interventions appeared to produce additive weight loss that approached the combined results of each intervention used alone. However, providing intensive lifestyle intervention and medication concurrently, rather than sequentially, has not achieved the same degree of additive benefit in placebo-controlled trials^{41,44}. For example, the concurrent provision of intensive lifestyle intervention (plus meal replacements) and semaglutide 2.4 mg in the STEP-3 trial produced a mean weight loss of 16.0%, which was comparable to that observed in the STEP-1 study (14.9%) in a similar population that did not receive this enhanced intensive lifestyle intervention^{21,41}.

The suggestion of additivity with sequential therapy, however, may be challenged by findings from preclinical studies. These studies have demonstrated that caloric restriction alone does not address the underlying physiology regulating body weight or fat mass, and antiobesity medication has the same overall ultimate effect regardless of whether or not caloric restriction preceded the medication⁴⁵. This implies that, if weight reduction in the lead-in period of the present trial was due only to a volitional reduction in caloric intake, the overall weight reduction of 24.3% could represent the effect the drug would have had even without an intensive lifestyle lead-in. Indeed, a recent 88 week trial of tirzepatide has demonstrated this degree of weight reduction as early as 52 weeks on treatment⁴⁶. The reason the weight reduction in the present trial may be higher than that observed in SURMOUNT-1 could be related to differences in demographics between the trial populations, or to the fact that this study, and other similarly designed trials, preselected for a highly responsive population by randomization of only participants who achieved an initial reduction of 5% or more with intensive lifestyle intervention. It is possible that participants who respond to lifestyle intervention are simply more responsive to tirzepatide. Further analyses should help examine this hypothesis.

Another major treatment issue concerns the intensity (that is, frequency) and scope of lifestyle intervention required with antiobesity medications. Weekly lifestyle visits and daily monitoring of food and energy intake historically have been required to help patients achieve and maintain the 500–750 kcal per day deficit needed to induce clinically meaningful weight loss¹⁶. Semaglutide and tirzepatide both appear to physiologically drive this reduction in energy intake, which might enable patients to implement dietary behavior changes with greater ease and efficiency than conventional lifestyle counseling. Similarly, weight loss induced with antiobesity medication, with the accompanying improvement in physical function observed in the present study, could increase patients' ease in engaging in physical activity, thus potentially further improving their cardiometabolic health.

The strengths of this study, which included an intensive lifestyle lead-in, include the fact that it had a relatively large sample size in which over one-third of the randomized population were men and over half were of Hispanic ethnicity. In addition, a 72-week treatment period facilitated at least 52 weeks of treatment with tirzepatide at MTD. The allowance of dose de- and re-escalation during the titration phase helped to maximize tolerability and reflected dose adjustment strategies that may be relevant for clinical practice.

The study's limitations include that it was geographically restricted to North and South America and that the study population was predominantly white, thus potentially limiting the generalizability of the findings. In addition, the 17.5% of participants who did not lose at least 5% of baseline weight in the intensive lifestyle intervention were not randomized to medication. To the extent that response to lifestyle intervention may predict response to medication, exclusion of these participants may have resulted in a higher mean weight loss with tirzepatide MTD than would have been observed if lifestyle nonresponders had been included. Trials of the response to antiobesity medications in persons who are unsuccessful with intensive lifestyle intervention are needed, because lack of success with lifestyle interventions has been a common prerequisite for initiation of pharmacotherapy or bariatric surgery. Future studies evaluating both genetic and behavioral predictors of response to lifestyle intervention and pharmacotherapy will help inform clinical management even earlier in the course of treatment.

In conclusion, in the SURMOUNT-3 trial, tirzepatide demonstrated clinically meaningful additional body weight reductions in adults with overweight or obesity following initial weight loss with intensive lifestyle intervention.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02597-w>.

References

- Global BMI Mortality Collaboration et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet* **388**, 776–786 (2016).
- Emmer, C., Bosnjak, M. & Mata, J. The association between weight stigma and mental health: a meta-analysis. *Obes. Rev.* **21**, e12935 (2020).
- US Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. *JAMA* **320**, 1163–1171 (2018).
- World Health Organization. Obesity and Overweight. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (accessed 8 August 2023).
- Jensen, M. D. et al. Guidelines (2013) for the management of overweight and obesity in adults. *Obesity* **22**, i–xvi (2014).
- Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* **346**, 393–403 (2002).
- Garvey, W. T. et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practical guidelines for medical care of patients with obesity. *Endocr. Pract.* **22**, 1–203 (2016).
- Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* **34**, 1481–1486 (2011).
- Wharton, S. et al. Obesity in adults: a clinical practice guideline. *CMAJ* **192**, e875–e891 (2020).
- Stegenga, H., Haines, A., Jones, K. & Wilding, J. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. *Br. Med. J.* **349**, g6608 (2014).
- Look Ahead Research Group et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N. Engl. J. Med.* **369**, 145–154 (2013).
- Gregg, E. W. et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol.* **4**, 913–921 (2016).
- Sjöström, L. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N. Engl. J. Med.* **357**, 741–752 (2007).
- Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Novo Nordisk <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166301#:~:text=Novo%20Nordisk%20A%2FS%3A%20Semaglutide%202.4%20mg%20reduces%20the,headline%20results%20from%20the%20SELECT%20cardiovascular%20outcomes%20trial> (accessed 11 August 2023).
- Hejmsfield, S. B. & Wadden, T. A. Mechanisms, pathophysiology, and management of obesity. *N. Engl. J. Med.* **376**, 254–266 (2017).
- Wadden, T. A., Tronieri, J. S. & Butryn, M. L. Lifestyle modification approaches for the treatment of obesity in adults. *Am. Psychol.* **75**, 235–251 (2020).
- Sumithran, P. et al. Long-term persistence of hormonal adaptations to weight loss. *N. Engl. J. Med.* **365**, 1597–1604 (2011).
- Ravussin, E. & Redman, L. M. Metabolic adaptation: is it really an illusion? *Am. J. Clin. Nutr.* **112**, 1653–1654 (2020).
- Rosenbaum, M. & Leibel, R. L. Models of energy homeostasis in response to maintenance of reduced body weight. *Obesity (Silver Spring)* **24**, 1620–1629 (2016).
- Jastreboff, A. M. & Kushner, R. F. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. *Ann. Rev. Med.* **74**, 125–139 (2023).
- Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. *N. Engl. J. Med.* **384**, 989–1002 (2021).
- Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat. Med.* **28**, 2083–2091 (2022).
- Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Mol. Metab.* **18**, 3–14 (2018).
- Samms, R. J., Coghlan, M. P. & Sloop, K. W. How may GIP enhance the therapeutic efficacy of GLP-1? *Trends Endocrinol. Metab.* **31**, 410–421 (2020).
- Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. *Nat. Rev. Endocrinol.* **19**, 201–216 (2023).
- Heise, T. et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. *Diabetes Care* **46**, 998–1004 (2023).
- Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. *N. Engl. J. Med.* **387**, 205–216 (2022).
- le Roux, C. W. et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. *Obesity (Silver Spring)* **31**, 96–110 (2023).
- Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int. J. Obes.* **37**, 1443–1451 (2013).

30. Hill, J. O. et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. *Am. J. Clin. Nutr.* **69**, 1108–1116 (1999).
31. Hall, K. D. & Kahan, S. Maintenance of lost weight and long-term management of obesity. *Med. Clin. North Am.* **102**, 183–197 (2018).
32. Perri, M. G. et al. Extended-care programs for weight management in rural communities: the Treatment of Obesity in Underserved Rural Settings (TOURS) randomized trial. *Arch. Intern. Med.* **168**, 2347–2354 (2008).
33. Svetkey, L. P. et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. *JAMA* **299**, 1139–1148 (2008).
34. Salminen, P. et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: The SLEEVEPASS randomized clinical trial. *JAMA Surg.* **157**, 656–666 (2022).
35. Foster, G. D., Wadden, T. A., Vogt, R. A. & Brewer, G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. *J. Consult. Clin. Psychol.* **65**, 79–85 (1997).
36. Lent, M. R. et al. Initial weight loss goals: have they changed and do they matter? *Obes. Sci. Pract.* **2**, 154–161 (2016).
37. Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* **402**, 613–626 (2023).
38. Mounjaro [package insert]. Indianapolis, IN, USA: Eli Lilly and Company (2023).
39. Wegovy [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S (2022).
40. Saxenda [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S (2023).
41. Wadden, T. A. et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. *JAMA* **325**, 1403–1413 (2021).
42. Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N. Engl. J. Med.* **373**, 11–22 (2015).
43. Tacad, D. K. M. et al. Satiety associated with calorie restriction and time-restricted feeding: peripheral hormones. *Adv. Nutr.* **13**, 792–820 (2022).
44. Wadden, T. A. et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. *Obesity (Silver Spring)* **28**, 529–536 (2020).
45. Stunkard, A. J. Anorectic agents lower a body weight set point. *Life Sci.* **30**, 2043–2055 (1982).
46. Eli Lilly and Company. Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies. *Eli Lilly and Company* <https://investor.lilly.com/news-releases/news-release-details/tirzepatide-demonstrated-significant-and-superior-weight-loss> (accessed 17 August 2023).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

¹Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ²Johns Hopkins School of Nursing, Baltimore, MD, USA. ³Division of Endocrinology and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. ⁴Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁵Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁶Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Pediatrics, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA. ⁷Vanderbilt Weight Loss Clinics, Vanderbilt University Medical Center, Nashville, TN, USA. ⁸Obesity Group, Department of Endocrinology, Universidade de São Paulo, São Paulo, Brazil. ⁹Eli Lilly and Company, Indianapolis, IN, USA. ✉ e-mail: wadden@pennmedicine.upenn.edu

Methods

Study design and participants

This 84-week, multicenter, randomized, parallel-arm, double-blind, placebo-controlled trial was conducted at 62 medical research centers in the USA, Argentina and Brazil. The study consisted of four periods: a 2-week screening period; a 12-week lead-in period during which participants received intensive lifestyle intervention to achieve $\geq 5.0\%$ body weight reduction; a 72-week double-blind, placebo-controlled treatment period (including a 20-week dose escalation period); and a 4-week safety follow-up period (Extended Data Fig. 4).

Eligible participants were ≥ 18 years of age and had obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related complication. Female enrollment was capped at 70% to ensure adequate representation of the male population. Full eligibility criteria are listed below.

Inclusion criteria

Participants were eligible for inclusion in the study only if all of the following criteria applied:

Type of participant and disease characteristics.

1. had a BMI of:
 - ≥ 30 kg/m² or
 - ≥ 27 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
 - hypertension: treated or with systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg
 - dyslipidemia: treated or with LDL ≥ 160 mg dl⁻¹ (4.1 mmol l⁻¹) or triglycerides ≥ 150 mg dl⁻¹ (1.7 mmol l⁻¹) or HDL < 40 mg dl⁻¹ (1.0 mmol l⁻¹) for men, or HDL < 50 mg dl⁻¹ (1.3 mmol l⁻¹) for women
 - obstructive sleep apnea
 - cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Classification Class I–III heart failure)
2. had a history of at least one self-reported unsuccessful dietary effort to lose body weight
3. in the investigator's opinion, were well motivated, capable and willing to:
 - learn how to self-inject study drug, as required for this protocol (visually impaired persons who were not able to perform the injections must have had the assistance of a sighted individual trained to inject the study drug; persons with physical limitations who were not able to perform the injections must have had the assistance of an individual trained to inject the study drug)
 - inject study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)
 - follow study procedures for the duration of the study, including—but not limited to—following lifestyle advice (for example, dietary restrictions, exercise plan), maintaining a study diary and completing required questionnaires

Participant characteristics.

4. were at least 18 years of age and age of majority according to local laws and regulations
 - a. male participants:
 - Male participants with partners of childbearing potential should have been willing to use reliable contraceptive methods throughout the study and for five half-lives of study drug plus 90 days, corresponding to 4 months after the last injection.

b. female participants:

- Female participants not of childbearing potential may have participated and included those who were:
 - infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or congenital anomaly (such as Mullerian agenesis) or
 - postmenopausal—defined as either:
 - a woman at least 40 years of age with an intact uterus, not on hormone therapy and who had cessation of menses for at least 1 year without an alternative medical cause, and follicle-stimulating hormone ≥ 40 mIU ml⁻¹; women in this category must have tested negative in pregnancy test before study entry
 - or
 - a woman 55 years or older not on hormone therapy and who had at least 12 months of spontaneous amenorrhea
 - or
 - a woman at least 55 years of age with a diagnosis of menopause before starting hormone replacement therapy
- Female participants of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopausal) must have:
 - tested negative for pregnancy at visit 1 based on a serum pregnancy test
 - if sexually active, agreed to use two forms of effective contraception where at least one form was highly effective for the duration of the trial plus 30 days, corresponding to 2 months after the last injection; and
 - not have been breastfeeding

Note: contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Informed consent.

5. Participants were required to be capable of giving signed informed consent, which included compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

Exclusion criteria

Participants were excluded from study enrollment if they met any of the following criteria at screening:

Medical conditions. Diabetes related.

6. had type 1 or type 2 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma
7. had at least one laboratory value suggestive of diabetes mellitus during screening, including one or more of: HbA1c $\geq 6.5\%$ (≥ 48 mmol mol⁻¹), fasting glucose ≥ 126 mg dl⁻¹ (≥ 7.0 mmol l⁻¹) or random glucose ≥ 200 mg dl⁻¹ (≥ 11.1 mmol l⁻¹)

Obesity related.

8. had a self-reported change in body weight > 5 kg within 3 months before screening
9. had a previous planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed > 1 year before screening)

10. had or planned to have endoscopic and/or device-based therapy for obesity or had device removal within the past 6 months before screening:
 - mucosal ablation
 - gastric artery embolization
 - intragastric balloon
 - duodenal–jejunal endoluminal liner

Other medical.

11. had renal impairment measured as $\text{eGFR} < 30 \text{ ml min}^{-1} 1.73 \text{ m}^{-2}$, calculated by Chronic Kidney Disease-Epidemiology as determined by central laboratory during screening
12. had a known clinically important gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronically took drugs that directly affect GI motility
13. had a history of chronic or acute pancreatitis
14. had thyroid-stimulating hormone (TSH) outside of the range $0.4\text{--}6.0 \text{ mIU l}^{-1}$ at the screening visit
 Note: participants receiving treatment for hypothyroidism may have been included, provided their thyroid hormone replacement dose had been stable for at least 3 months and their TSH at screening fell within the range indicated above.
 Note: participants with a history of subclinical hypothyroidism but a TSH at screening within the range indicated above may have been included if, in the investigator's opinion, the patient was unlikely to require initiation of thyroid hormone replacement during the course of the study.
15. had obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency or Prader–Willi syndrome)
16. had a history of substantial active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder or other serious mood or anxiety disorder) within the past 2 years
 Note: participants with MDD or generalized anxiety disorder and whose disease state was considered stable for the past 2 years and was expected to remain stable throughout the course of the study, in the opinion of the investigator, may have been considered for inclusion if they were not on excluded medications
17. had a lifetime history of suicide attempt
18. had a PHQ-9 score of 15 or more at visit 1
19. on the Columbia Suicide Severity Rating Scale (C-SSRS) at any time from visit 1 to visit 2:
 - a 'yes' answer to Question 4 (active suicidal ideation with some intent to act, without specific plan) on the 'Suicidal Ideation' portion of the C-SSRS
 - or
 - a 'yes' answer to Question 5 (active suicidal ideation with specific plan and intent) on the 'Suicidal Ideation' portion of the C-SSRS
 - or
 - a 'yes' answer to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the 'Suicidal Behavior' portion of the C-SSRS and
 - the ideation or behavior occurred within the past month
20. had uncontrolled hypertension (systolic blood pressure $\geq 160 \text{ mmHg}$ and/or diastolic blood pressure $\geq 100 \text{ mmHg}$)
21. had any of the following cardiovascular conditions within 3 months before visit 2:
 - acute myocardial infarction
 - cerebrovascular accident (stroke)

- unstable angina
- hospitalization due to congestive heart failure

22. had New York Heart Association Functional Classification Class IV congestive heart failure
23. had acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD) or any of the following, as determined by the central laboratory during screening:
 - alanine aminotransferase level > 3.0 times upper limit of normal (ULN) for the reference range
 - alkaline phosphatase level > 1.5 times ULN for the reference range
 - total bilirubin level > 1.2 times ULN for the reference range (except for cases of known Gilbert syndrome)

Note: participants with NAFLD were eligible to participate in this trial if their alanine aminotransferase level was ≤ 3.0 times ULN for the reference range.

24. had a serum calcitonin level (at visit 1) of
 - $\geq 20 \text{ ng l}^{-1}$, if $\text{eGFR} \geq 60 \text{ ml min}^{-1} 1.73 \text{ m}^{-2}$
 - $\geq 35 \text{ ng l}^{-1}$, if $\text{eGFR} < 60 \text{ ml min}^{-1} 1.73 \text{ m}^{-2}$
25. had a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
26. had a history of an active or untreated malignancy or were in remission from a clinically important malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix or in situ prostate cancer) for < 5 years
27. had any other condition not listed in this section (for example, hypersensitivity or intolerance) that is a contraindication to GLP-1 R agonists
28. had a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder or other psychiatric disorder) that, in the opinion of the investigator, may have precluded the participant from following and completing the protocol
29. had a history of use of marijuana or tetrahydrocannabinol-containing products within 3 months of enrollment, or unwillingness to abstain from marijuana or tetrahydrocannabinol-containing products use during the trial
 Note: if a participant had used cannabidiol oil during the past 3 months but agreed to refrain from use for the duration of the study, the participant could be enrolled.
30. had had a transplanted organ (corneal transplants (keratoplasty) were allowed) or were awaiting an organ transplant
31. had any hematological condition that may have interfered with HbA1c measurement (for example, hemolytic anemias, sickle cell disease)

Previous and/or concomitant therapy.

32. were receiving or had received within 3 months before screening chronic (> 2 weeks or 14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular or inhaled preparations) or had evidence of a substantial, active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that had required (within the past 3 months) or was likely to require, in the opinion of the investigator, concurrent treatment with systemic glucocorticoids (excluding topical, intraocular, intranasal, intra-articular or inhaled preparations) during the course of the study
33. had current treatment with or history of (within 3 months before visit 2) treatment with medications that may cause

substantial weight gain, including but not limited to: tricyclic antidepressants, atypical antipsychotics and mood stabilizers
Examples:

- imipramine
- amitriptyline
- mirtazapine
- paroxetine
- phenelzine
- chlorpromazine
- thioridazine
- clozapine
- olanzapine
- valproic acid (and its derivatives) or
- lithium

Note: selective serotonin reuptake inhibitors other than paroxetine were permitted.

34. had taken, within 3 months before visit 2, medications (prescribed or over-the-counter) or alternative remedies that promote weight loss

Examples included, but were not limited to

- Saxenda (liraglutide 3.0 mg)
- Xenical/Alli (orlistat)
- Meridia (sibutramine)
- Acutrim (phenylpropanolamine)
- Sanorex (mazindol)
- Apidex (phentermine)
- BELVIQ (lorcaserin)
- Bontril (phendimetrazine)
- Qsymia (phentermine/topiramate combination)
- Contrave (naltrexone/bupropion)

Note: use of metformin, or any other glucose-lowering medication, whether prescribed for polycystic ovarian syndrome or diabetes prevention, was not permitted.

35. had started implantable or injectable contraceptives (such as Depo Provera) within 18 months before screening

Previous and/or concurrent clinical study experience.

36. were currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
37. within the past 30 days had participated in a clinical study and received treatment, whether active or placebo. If the study involved an investigational product, five half-lives or 30 days, whichever was longer, should have passed.
38. had previously completed or withdrawn from this study or any other study investigating tirzepatide after receiving at least one dose of investigational product

Other exclusions.

39. were investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family was defined as a spouse, parent, child or sibling, whether biological or legally adopted.
40. were Lilly employees

This study is registered with ClinicalTrials.gov, [NCT04657016](https://clinicaltrials.gov/ct2/show/study/NCT04657016). The protocol was approved by local institutional review boards and the trial complied with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent.

Lead-in period

Eligible participants were enrolled in a 12-week intensive lifestyle intervention lead-in period. The lead-in lifestyle intervention included frequent in-person lifestyle counseling sessions (that is, eight sessions over 12 weeks), delivered by a dietitian or similarly qualified healthcare professional. Women were instructed to consume approximately 1,200 kcal per day and men 1,500 kcal per day. The dietary intervention could include up to two meal replacements (liquid meal replacements or prepackaged, portion-controlled meals) per day. Participants were encouraged to engage in at least 150 min of moderate-intensity physical activity per week (for example, brisk walking). They were counseled on behavior modification strategies to help implement and adhere to the diet and exercise recommendations, and were encouraged to complete 3-day diet and exercise logs before each counseling visit.

Randomization for the double-blind treatment period

Participants who achieved $\geq 5.0\%$ weight reduction at the end of the 12-week lead-in period were randomly assigned in a 1:1 ratio to receive either the MTD of tirzepatide (10 or 15 mg) or placebo. Assignment to treatment group was determined by a computer-generated random sequence using a validated interactive web-response system. All participants, investigators and the sponsor were masked to treatment assignment. To maintain masking of participants and site staff, the single-dose pens were identical between active product and placebo. Randomization was stratified according to country, sex (female, male) and per cent weight reduction at the end of lead-in (<10 versus $\geq 10\%$).

Procedures during the double-blind treatment period

Tirzepatide and matched placebo were administered once weekly as a subcutaneous injection using a single-dose pen. The starting dose of tirzepatide was 2.5 mg, increasing by 2.5 mg every 4 weeks until an MTD dose of 10 or 15 mg was reached. To optimize tolerability and adherence, gastrointestinal symptoms could be managed by dietary counseling, symptomatic medications according to the investigator's discretion or skipping of a single dose of treatment. During the first 24 weeks of the treatment period, if these mitigations were not successful one cycle of tirzepatide dose de- and re-escalation (in 2.5 mg increments) was allowed for participants unable to tolerate any dose between 7.5 and 15 mg inclusive; participants unable to tolerate 2.5 or 5 mg were discontinued from study drug but remained in the study for continued follow-up. Participants who did not tolerate up to 10 mg even after one de- and re-escalation attempt were discontinued from study drug but remained in the study for continued follow-up. Dose adjustments were not permitted after the first 24 weeks of treatment.

Throughout the postrandomization period, participants continued to consult with a dietitian or other qualified healthcare professional. Lifestyle counseling sessions occurred every 12 weeks and focused on consumption of a healthy balanced diet, with a 500 kcal per day deficit and continuation of physical activity. Use of the diet and exercise log was encouraged. In between counseling sessions, diet and exercise goals were reinforced by site staff at every monthly visit.

Participants were permitted to use concomitant medications that they required during the study, except for certain agents specified in the protocol that could interfere with the assessment of efficacy and safety characteristics of the study treatments.

Study outcomes

Coprimary endpoints were per cent change in body weight and the proportion of study participants who achieved $\geq 5\%$ weight reduction from randomization to week 72. Key secondary endpoints, controlled for type 1 error rate, included the proportion of study participants who achieved ≥ 10 , ≥ 15 or $\geq 20\%$ weight reduction from randomization to week 72. The proportion of study participants who achieved $\geq 25\%$ reduction in body weight was a prespecified exploratory endpoint. Key secondary endpoints also included the proportion of participants who,

at week 72, maintained $\geq 80\%$ of the body weight loss achieved during the 12-week lead-in period, as well as change in waist circumference (cm) from randomization to week 72.

Additional secondary endpoints included change in anthropometrics (absolute body weight and BMI), cardiometabolic risk factors (blood pressure, lipids, fasting glucose, HbA_{1c} and fasting insulin) and patient-reported outcomes (the Physical Functioning domain score on the SF-36v2 acute form, and the IWQOL-Lite-CT Physical Function composite score). These additional secondary endpoints were evaluated both from randomization (week 0) and from the start of the lead-in period (week -12) to week 72.

In addition, changes in the intensity of antihypertensive and lipid-lowering therapies in the double-blind period, as reported by the investigator, were assessed as prespecified exploratory endpoints.

Safety endpoints included treatment-emergent adverse events and serious adverse events that occurred during the reporting period. Major adverse cardiovascular events, acute pancreatitis and deaths were reviewed by an independent external adjudication committee.

Statistical analysis

A sample size of 600 participants provided power of $>90\%$ to demonstrate the superiority of tirzepatide MTD to placebo, for the coprimary endpoints, each at a two-sided significance level of 0.05. Sample size calculation assumed a difference of at least 12% in mean per cent weight reduction from randomization to week 72 for tirzepatide MTD as compared with placebo, a common s.d. of 10% and a dropout rate of 25%. Efficacy and safety endpoints were analyzed with data from all randomly assigned participants who took at least one dose of study drug (modified intention-to-treat population).

Two estimands (TRE and efficacy) were used to assess treatment efficacy from different perspectives and accounted for intercurrent events differently.

The TRE uses a treatment policy strategy to handle intercurrent events (ICH E9(R1)) and is intended to give an estimation of the average treatment effect of tirzepatide relative to placebo for all participants who had undergone randomization, regardless of treatment adherence. For estimation for this estimand, the intercurrent events and resulting missing values were handled by a hybrid approach using retrieved dropouts imputation from the same treatment group or using all nonmissing data assuming missing at random. This estimand is therefore also referred to as a 'hybrid' estimand in the study protocol. Continuous endpoints were analyzed using an analysis of covariance model, and categorical endpoints were analyzed by logistical regression. Both models included randomized treatment and stratification factors (country/pooled country, sex and per cent body weight reduction at the end of lead-in (<10 and $\geq 10\%$) as fixed effects, and baseline measure as a covariate. Analyses were conducted with hybrid imputation of missing body weight at 72 weeks and statistical inference over hybrid imputation of missing data guided by Rubin⁴⁷.

Specifically, for missing data solely due to COVID-19, missing data were considered as missing at random and imputed using all available nonmissing data of the outcome measurement from the same treatment arm; for missing data due to other intercurrent events, these were imputed based on retrieved dropouts in the same treatment arm, defined as observed primary outcome measurements, from participants in the same treatment group, who had their efficacy assessed after early discontinuation of the study drug.

The efficacy estimand uses a hypothetical strategy to handle intercurrent events (ICH E9(R1)) and represented the average treatment effect of tirzepatide relative to placebo, before treatment discontinuation, for all participants who had undergone randomization. The resulting missing values (unobserved, discarded) after treatment discontinuation were implicitly handled using a mixed model for repeated measures (MMRM) under the assumption of missing at random. Continuous endpoints were analyzed using a MMRM model,

and categorical endpoints by logistical regression. MMRM analysis included randomized treatment, visit, treatment-by-visit interaction and stratification factors (country/pooled country, sex and per cent body weight reduction at the end of lead-in (<10 and $\geq 10\%$) as fixed effects, and baseline measure as a covariate. The logistical regression model included randomized treatment, the same stratification factors as fixed effects and baseline measure as a covariate. Missing values were imputed by the predicted value from the MMRM model above, and continuous measurements were then dichotomized to binary outcomes. The type 1 error rate was controlled at a level of 0.05 within each estimand for evaluation of primary and key secondary objectives.

Statistical analyses were carried out using SAS v.9.4, unless otherwise specified.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, except for pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the USA and European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data have been made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data-sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

References

47. Rubin, D. B. *Multiple Imputation for Nonresponse in Surveys* (John Wiley & Sons, 1987).

Acknowledgements

We, and Eli Lilly and Company, thank the clinical trial participants and their caregivers, as well as the clinical trial investigators (listed in Supplementary Information), without whom this work would not have been possible. We also thank J. Daly and A. Hemmingway (Eli Lilly and Company) for medical writing and editorial support. The study was funded by Eli Lilly and Company. Eli Lilly and Company contributed to the study design, oversaw the conduct of the study and provided medical writing and editorial support for this Article.

Author contributions

N.N.A., M.C.B. and S.Z. contributed to the study design. T.A.W., A.M.C., S.M., G.S. and B.H. conducted the trial and collected data. J.C. and S.Z. were responsible for statistical analyses. S.Z., J.C., N.N.A., M.C.B. and T.F. are the guarantors of this work and, as such, take responsibility for the integrity of the data and the accuracy of data analysis. All authors participated in data interpretation, manuscript writing (assisted by a medical writer paid for by the funder) and critical review of the manuscript, had full access to all the data in the study and approved the submission of this manuscript for publication.

Competing interests

T.A.W. reports grants or contracts from Novo Nordisk, Epitome Medical Co. and Eli Lilly and Company; and service on Scientific Advisory Boards for Novo Nordisk and WW. A.M.C. reports grants or contracts from National Institutes of Health, WW International, Inc, The Edna G. Kynett Memorial Foundation, Novo Nordisk and Epitome Medical; consulting fees from Eli Lilly and Company and

Boehringer Ingelheim; and payment or honoraria for presentation and travel/meeting support from the Obesity Medicine Association. S.M. reports grants or contracts from Boehringer Ingelheim, Rhythm Pharmaceuticals and Novo Nordisk; consulting fees from Novo Nordisk, Rhythm Pharmaceuticals and Eli Lilly and Company; payment or honoraria from Columbia University Medical Center, Boston Obesity Course in Obesity medicine and Medical College of Wisconsin; and participation on Advisory Boards for Novo Nordisk and Eli Lilly and Company. R.K. reports participation on a Data Safety Monitoring Board or Advisory Board for Eli Lilly and Company, Novo Nordisk and Boehringer Ingelheim. J.A. reports grants or contracts from Nestle Healthcare Nutrition, Eli Lilly and Company, Boehringer Ingelheim, Epitech, Inc., UnitedHealth Group R&D, KVK Tech and WW; consulting fees from Nestle Healthcare Nutrition, Eli Lilly and Company, Optum Labs R&D, Novo Nordisk, Spokes Health, Inc., Intuitive, Regeneron, Brightseed, Level2 and WW; receipt of equipment, materials, drugs, medical writing, gifts or other services from KVK Tech, WW and Nestle Healthcare Nutrition; and is President Elect of The Obesity Society and an Executive Board Member of the American Society for Nutrition Foundation. G.S. reports consulting fees from Rhythm Pharmaceuticals, Novo Nordisk and Eli Lilly and Company; and speaker's bureau from Novo Nordisk. B.H. reports payment or honoraria from Eli Lilly and Company, Novo Nordisk, Merck S.A., Astra Zeneca and Abbott Nutrition; travel/meeting support from Novo Nordisk; participation on a Data Safety Monitoring

Board or Advisory Board for Eli Lilly, Novo Nordisk and Merck S.A.; receipt of equipment, materials, drugs, medical writing, gifts or other services from Eli Lilly and Company and Novo Nordisk; and is President of the Brazilian Association of Obesity and a Member of Board of Trustees of World Obesity Federation representing Latin America. S.Z., J.C., M.C.B., N.N.A. and T.F. are employees and shareholders of Eli Lilly and Company.

Additional information

Extended data is available for this paper at


<https://doi.org/10.1038/s41591-023-02597-w>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02597-w>.

Correspondence and requests for materials should be addressed to Thomas A. Wadden.


Peer review information *Nature Medicine* thanks Victor Volovici, John Wilding and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Jennifer Sargent, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Body weight in kg over time. Mean (standard error) body weight (kg) over time from randomization to 72 weeks derived from a mixed-model for repeated measures (MMRM) analysis for the efficacy estimand.

Only participants with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis. MTD, maximum tolerated dose (10 or 15 mg).



Extended Data Fig. 2 | Blood pressure change from start of lead-in period over time. Panel A, mean (95% confidence interval) change from baseline over time in systolic blood pressure from start of intensive-lifestyle intervention lead-in period (week -12) to 72 weeks using observed means. Week 72 estimates for the efficacy estimand (EFF) are also shown. Panel B, mean (95% confidence interval)


change from baseline over time in diastolic blood pressure from start of intensive-lifestyle intervention lead-in period (week -12) to 72 weeks using observed means. Week 72 estimates for the efficacy estimand (EFF) are also shown.



Extended Data Fig. 3 | Incidence of nausea, vomiting, and diarrhea over time.

The percentage of participants receiving tirzepatide or placebo who reported nausea, vomiting, or diarrhea are presented. Percentages are based on number

of participants at risk at specific observation time. Events were classed as mild (shown in green), moderate (shown in orange), or severe (shown in red). MTD, maximum tolerated dose (10 or 15 mg); T2P, tirzepatide.



Extended Data Fig. 4 | SURMOUNT-3 study design. This is a phase 3, multicenter, randomized, placebo-controlled, double-blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have

obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in. All randomized participants were planned to undergo a 72-week treatment period.

Extended Data Table 1 | Demographics of Participants in the United States

Characteristics	Tirzepatide MTD (N=185)	Placebo (N=188)	Total (N=373)
Age, mean (SD), years	47.3 (12.3)	48.1 (11.3)	47.7 (11.8)
Sex, n (%)			
Female	116 (62.7)	118 (62.8)	234 (62.7)
Male	69 (37.3)	70 (37.2)	139 (37.3)
Race ^a , n (%)			
Asian	1 (0.5)	1 (0.5)	2 (0.5)
Black or African American	18 (9.7)	17 (9.0)	35 (9.4)
Multiple	5 (2.7)	2 (1.1)	7 (1.9)
American Indian or Alaska	2 (1.1)	4 (2.1)	6 (1.6)
White	159 (85.9)	164 (87.2)	323 (86.6)
Ethnicity, n (%)			
Hispanic or Latino	59 (31.9)	61 (32.4)	120 (32.2)
Not Hispanic or Latino	125 (67.6)	126 (67.0)	251 (67.3)
Not reported	1 (0.5)	1 (0.5)	2 (0.5)

^aRace and ethnicity were determined by the participant according to fixed selection categories. MTD, maximum tolerated dose (10 or 15 mg).

Extended Data Table 2 | Additional Efficacy Findings from Start of Intensive Lifestyle Intervention Lead-In (Week-12) to Week 72 (Efficacy Estimand)

	Least squares mean (SE)		Treatment comparison
	Tirzepatide MTD (N=287)	Placebo (N=292)	Difference from placebo (95% CI)
Percent change in body weight, %	-26.6 (0.5)	-3.8 (0.6)	ETD -22.8 (-24.3, -21.2)
Change in body weight, kg	-29.2 (0.7)	-4.1 (0.7)	ETD -25.1 (-26.9, -23.2)
Change in BMI, kg/m ²	-10.4 (0.2)	-1.4 (0.2)	ETD -8.9 (-9.6, -8.3)
Change in waist circumference, cm	-23.4 (0.6)	-5.6 (0.6)	ETD -17.8 (-19.4, -16.1)
Change in SBP, mmHg	-10.5 (0.7)	-0.9 (0.8)	ETD -9.6 (-11.7, -7.5)
Change in DBP, mmHg	-6.2 (0.5)	-0.8 (0.6)	ETD -5.4 (-6.9, -3.9)
Percent change in total cholesterol	-6.3 (0.9)	-0.3 (1.1)	ETD -6.0 (-8.6, -3.2)
Percent change in non-HDL cholesterol	-13.1 (1.2)	-0.9 (1.5)	ETD -12.3 (-15.7, -8.8)
Percent change in HDL cholesterol	13.1 (1.1)	1.4 (1.1)	ETD 11.5 (8.3, 14.7)
Percent change in LDL cholesterol	-7.4 (1.5)	1.3 (1.7)	ETD -8.6 (-12.6, -4.3)
Percent change in VLDL cholesterol	-33.1 (1.4)	-8.1 (2.0)	ETD -27.2 (-31.3, -22.8)
Percent change in triglycerides	-33.2 (1.4)	-8.8 (2.0)	ETD -26.8 (-31.0, -22.4)
Percent change in free fatty acids	-26.6 (2.5)	-5.9 (3.4)	ETD -21.9 (-29.2, -14.0)
Change in fasting glucose, mg/dl	-11.5 (0.8)	-0.2 (0.9)	ETD -11.3 (-13.6, -8.9)
Change in HbA1c, %	-0.6 (0.0)	-0.1 (0.0)	ETD -0.5 (-0.6, -0.4)
Percent change in fasting insulin	-56.7 (1.6)	-17.8 (3.3)	ETD -47.3 (-52.7, -41.3)
Change in SF-36v2 Physical Functioning domain score ^a	6.1 (0.4)	2.5 (0.4)	ETD 3.6 (2.5, 4.7)
Change in IWQOL-Lite-CT Physical Function composite score ^b	27.8 (1.1)	14.5 (1.2)	ETD 13.2 (10.0, 16.5)

BMI, body mass index; DBP, diastolic blood pressure; ETD, estimated treatment difference; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IWQOL-Lite-CT, Impact of Weight on Quality of Life-Lite-Clinical Trials Version; LDL-C, low-density lipoprotein cholesterol; MTD, maximum tolerated dose (10 or 15 mg); SBP, systolic blood pressure; SF-36v2, Short Form-36 version 2 Health Survey acute form; VLDL-C, very low-density lipoprotein cholesterol. ^aThe SF-36v2 measures health-related quality of life and general health status. The SF-36v2 scores are norm-based scores, ie, scores transformed to a scale in which the 2009 US general population has a mean score of 50 and an SD of 10. An increase in score represents an improvement in health status. ^bThe IWQOL-Lite-CT measures weight-specific health-related quality of life. All items are rated on either a 5-point frequency scale ('never' to 'always') or a 5-point truth scale ('not at all true' to 'completely true'). Scores are transformed to a scale of 0 to 100, with higher scores reflecting better levels of functioning.

Extended Data Table 3 | Additional Safety Measures from Randomization to Week 72

	Tirzepatide MTD (N=287)	Placebo (N=292)
Pulse rate, beats/minute		
Baseline	72.2 (0.62)	70.7 (0.62)
Week 72	74.0 (0.53)	72.2 (0.57)
Change at week 72	2.7 (0.53)	0.9 (0.57)
Pancreatic amylase, IU/L		
Baseline	24.0 (0.53)	25.4 (0.56)
Week 72	30.3 (0.50)	24.8 (0.44)
Percent change at week 72	22.8 (2.03)	0.6 (1.79)
Lipase, IU/L		
Baseline	27.6 (0.63)	28.4 (0.66)
Week 72	41.3 (0.99)	30.3 (0.78)
Percent change at week 72	46.6 (3.50)	7.7 (2.78)
Alanine Aminotransferase, IU/L		
Baseline	21.4 (0.58)	20.6 (0.56)
Week 72	16.9 (0.49)	21.1 (0.66)
Percent change at week 72	-18.9 (2.35)	1.5 (3.17)
Aspartate Aminotransferase, IU/L		
Baseline	20.1 (0.38)	19.3 (0.37)
Week 72	18.3 (0.39)	20.0 (0.46)
Percent change at week 72	-6.8 (2.00)	2.0 (2.37)
Calcitonin, ng/L		
Baseline	1.6 (0.07)	1.5 (0.06)
Week 72	1.7 (0.05)	1.6 (0.05)
Percent change at week 72	12.0 (3.35)	3.9 (3.30)
Urine albumin-creatinine ratio, g/kg		
Baseline	5.8 (0.33)	6.0 (0.35)
Week 72	5.2 (0.26)	5.4 (0.30)
Percent change at week 72	-12.3 (4.47)	-8.8 (5.06)

Data are model based estimate (standard error) and were analyzed with log transformation, except for pulse rate data. MTD, maximum tolerated dose (10 or 15 mg).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
<input type="checkbox"/>	<input checked="" type="checkbox"/> The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
<input checked="" type="checkbox"/>	<input type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
<input type="checkbox"/>	<input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/> A description of all covariates tested
<input checked="" type="checkbox"/>	<input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
<input type="checkbox"/>	<input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
<input type="checkbox"/>	<input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
<input checked="" type="checkbox"/>	<input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No specific software was used for data collection; the collected data were entered using the Veeva Vault Clinical Data Management Suite (CDMS) electronic data collection system.
Data analysis	Statistical analyses were done using SAS version 9.4, unless otherwise specified.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Lilly provides access to all individual participant data collected during the trial, after anonymization, except for pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at [www.vivli.org](#).

The protocol and statistical analysis plan are included in the supplementary material.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Patients were screened and enrolled irrespective of their sex. Female enrollment was capped at 70% to ensure adequate representation of the male population. Any data on sex was collected at each clinical trial site. Data are provided in Table 2 and Extended Data Table 1.

Reporting on race, ethnicity, or other socially relevant groupings

Patients were screened and enrolled irrespective of their race/ethnicity. Data are provided in Table 2 and Extended Data Table 1.

Population characteristics

Provided in Table 2 and Extended Data Table 1.

Recruitment

Took place in medical research centers in the United States, Argentina, and Brazil.

Ethics oversight

The protocol was approved by local institutional review boards, and the trial complied with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. The ethics review boards were Comit  de  tica Independente Consultorias Integradas Ceici, COMIT  DE  TICA EN INVESTIGACION CLINICA CEIC, COMIT  DE  TICA SAAVEDRA, Centro de Investigaciones Metab licas (CIMV), CEMEDIAB, INVESTIGA - INSTITUTO DE PESQUISA, Comit  de  tica em Pesquisa em S eres Humanos do Hospital P ri-Card cio, Comit  de  tica em Pesquisa Faculdade de Medicina do ABC, Comit  de  tica em Pesquisa em S eres Humanos - Centro Integrado de At en o   Sa de - CIAS - UNIMED, Instituto de Sa de e Bem-Estar da Mulher (ISBEM), Comit  de  tica em Pesquisa em S eres Humanos HC-UFPR, Instituto de Sa de e Bem-Estar da Mulher (ISBEM), Universidade Positivo, Advarra Inc., and Vanderbilt Human Research Protections Program.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The sample size was determined based on achieving approximately 600 participants randomly assigned to study drug intervention (300 participants per treatment group). Sample size determination assumed that evaluation of superiority of tirzepatide MTD (10 mg or 15 mg) to placebo would be conducted at a 2-sided significance level of 0.05 using a 2-sample t-test. Additionally, a difference of at least 12% mean body weight percentage reduction from randomization at 72 weeks for tirzepatide MTD compared to placebo, a common SD of 10%, and a dropout rate of 25% were assumed for statistical power calculations. Under the assumptions above, randomizing 600 participants in a 1:1 ratio to MTD (300 participants) and placebo (300 participants) provided more than 90% power to demonstrate superiority of tirzepatide MTD to placebo. The chosen sample size and randomization ratio also provided >90% power to establish superiority of tirzepatide MTD to placebo in terms of proportion of participants achieving at least 5% body weight reduction from randomization at 72 weeks, based on a Chi-square test at a 2-sided significance level of 0.05, assuming 20% placebo treated participants and 46% tirzepatide treated participants achieved the goal and a dropout rate of 25%.

Data exclusions

In this study, all randomly assigned participants took at least one dose of study intervention. Therefore, the intention-to-treat population is the same as the modified intention-to-treat population. Two estimands, (treatment-regimen estimand and efficacy estimand), were used to assess treatment efficacy from different perspectives and accounted for intercurrent events differently. The treatment-regimen estimand represented the average treatment effect of tirzepatide relative to placebo for all participants who had undergone randomization, regardless of treatment adherence. The efficacy estimand represented the average treatment effect of tirzepatide relative to placebo, prior to treatment discontinuation, for all participants who had undergone randomization.

Replication

Results were consistent between the protocol defined estimands. This study is part of a broader phase 3 program (SURMOUNT).

Randomization

Participants who achieved $\geq 5.0\%$ weight reduction at the end of the 12-week lead-in period were randomly assigned in a 1:1 ratio to receive either the maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) or placebo. Assignment to treatment group was determined by a computer-generated random sequence using a validated interactive web-response system. Randomization was stratified according to country, sex (female, male), and percent weight reduction at the end of lead-in ($<10\%$ versus $\geq 10\%$).

Blinding

All participants, investigators, and the sponsor were masked to treatment assignment. To maintain masking of participants and site staff, the single-dose pens were identical between active product and placebo.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Research sample

Sampling strategy

Data collection

Timing

Data exclusions

Non-participation

Randomization

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<input type="text"/>
Research sample	<input type="text"/>
Sampling strategy	<input type="text"/>
Data collection	<input type="text"/>
Timing and spatial scale	<input type="text"/>
Data exclusions	<input type="text"/>
Reproducibility	<input type="text"/>
Randomization	<input type="text"/>
Blinding	<input type="text"/>

Did the study involve field work? ☐ Yes ☐ No

Field work, collection and transport

Field conditions	<input type="text"/>
Location	<input type="text"/>
Access & import/export	<input type="text"/>
Disturbance	<input type="text"/>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used	<input type="text"/>
Validation	<input type="text"/>

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Authentication

Mycoplasma contamination

Commonly misidentified lines
(See [ICLAC](#) register)

Palaeontology and Archaeology

Specimen provenance

Specimen deposition

Dating methods

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

Wild animals

Reporting on sex

Field-collected samples

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration ClinicalTrials.gov, NCT04657016

Study protocol Provided in the supplementary material

Data collection Data were collected at 62 individual medical research centres in the United States, Argentina, and Brazil. The first participant was enrolled on 12th April 2021 and the last participant on 3rd September 2021, with the last participant's last visit occurring on 12th May 2023.

Outcomes Primary and secondary objectives and endpoints were pre-specified in the protocol and statistical analysis plan. Co-primary endpoints were the percent change in body weight and the proportion of study participants who achieved $\geq 5\%$ weight reduction from randomization to week 72. Key secondary endpoints controlled for type 1 error rate included the proportion of study participants who achieved $\geq 10\%$, $\geq 15\%$, or $\geq 20\%$ weight reductions from randomization to week 72, the proportion of participants who, at week 72, maintained $\geq 80\%$ of the body weight loss achieved during the 12-week lead-in period, and the change in waist circumference (cm) from randomization to week 72.

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
<input type="checkbox"/>	<input type="checkbox"/> Public health
<input type="checkbox"/>	<input type="checkbox"/> National security
<input type="checkbox"/>	<input type="checkbox"/> Crops and/or livestock
<input type="checkbox"/>	<input type="checkbox"/> Ecosystems
<input type="checkbox"/>	<input type="checkbox"/> Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
<input type="checkbox"/>	<input type="checkbox"/> Demonstrate how to render a vaccine ineffective
<input type="checkbox"/>	<input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents
<input type="checkbox"/>	<input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent
<input type="checkbox"/>	<input type="checkbox"/> Increase transmissibility of a pathogen
<input type="checkbox"/>	<input type="checkbox"/> Alter the host range of a pathogen
<input type="checkbox"/>	<input type="checkbox"/> Enable evasion of diagnostic/detection modalities
<input type="checkbox"/>	<input type="checkbox"/> Enable the weaponization of a biological agent or toxin
<input type="checkbox"/>	<input type="checkbox"/> Any other potentially harmful combination of experiments and agents

Plants

Seed stocks	<input type="text"/>
Novel plant genotypes	<input type="text"/>
Authentication	<input type="text"/>

ChIP-seq

Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	<input type="text"/>
Files in database submission	<input type="text"/>
Genome browser session (e.g. UCSC)	<input type="text"/>

Methodology

Replicates	<input type="text"/>
Sequencing depth	<input type="text"/>
Antibodies	<input type="text"/>
Peak calling parameters	<input type="text"/>
Data quality	<input type="text"/>
Software	<input type="text"/>

Flow Cytometry

Plots

Confirm that:

- ☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

- Sample preparation
- Instrument
- Software
- Cell population abundance
- Gating strategy
- ☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

- Design type
- Design specifications
- Behavioral performance measures
- Imaging type(s)
- Field strength
- Sequence & imaging parameters
- Area of acquisition
- Diffusion MRI ☐ Used ☐ Not used

Preprocessing

- Preprocessing software
- Normalization
- Normalization template
- Noise and artifact removal
- Volume censoring

Statistical modeling & inference

- Model type and settings
- Effect(s) tested
- Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ Both

Statistic type for inference

(See [Eklund et al. 2016](#))

Correction

Models & analysis

n/a | Involved in the study

- | | | |
|--------------------------|--------------------------|--|
| <input type="checkbox"/> | <input type="checkbox"/> | Functional and/or effective connectivity |
| <input type="checkbox"/> | <input type="checkbox"/> | Graph analysis |
| <input type="checkbox"/> | <input type="checkbox"/> | Multivariate modeling or predictive analysis |

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis

